Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 1.00 |
| ▸ | BCR | P11274 | 19/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450466 | 0.88 | ABL1 (0.79) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3399556 | 0.88 | ABL1 (0.78) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3396370 | 0.86 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL22440783 | 0.86 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL18696372 | 0.86 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3399322 | 0.86 | ABL1 (0.77) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL18231590 | 0.86 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL18696377 | 0.85 | ABL1 (0.74) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL12943197 | 0.85 | ABL1 (0.74) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL21338339 | 0.84 | ABL1 (0.72) | ABL1BCRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009091476-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | IRM LLC (BM) | 2009-07-23 | — | — | WO | disclosed |
| EP-1613595-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-01 | — | — | EP | disclosed |
| CN-1798734-A | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-07-05 | — | — | CN | disclosed |
| EP-1613595-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-11 | — | — | EP | disclosed |
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2004089286-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014753-A1 | Novel compounds and compositions as protein kinase inhibitors | ABL1, BCR, PDGFRA | ABL1 1/4885BCR 2/4885KDM4E 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.